PD-L1 is upregulated in cancers, such as glioblastoma (Wang et al., 2016), ovarian cancer (Abiko et al., 2013), lung cancer and oral carcinoma (Kim et al., 2005; Ota et al., 2015), and upregulated PD-L1 predicts worse survival. This evidence concerns the gene CD274 and cancer.